source
- Vertex reports early kidney drug data, boosting hopes for broad label ahead of next year's pivotal readoutVertex Pharmaceuticals disclosed early data from its experimental kidney disease therapy inaxaplin, showing improvements on a urine-based biomarker. The drug demonstrated positive changes in two s…
- Celldex's barzolvolimab meets Phase 3 goals but safety concerns emergeCelldex announced that its experimental chronic hives treatment, barzolvolimab, achieved the primary endpoint in two Phase 3 trials. The trials demonstrated the drug's efficacy in reducing hive sy…